Canaccord Genuity analyst Sumant Kulkarni raised the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $84.00 (from $81.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

BioXcel Therapeutics (BTAI) PT Raised to $50 at GuggenheimApril 7, 2022 7:17 AM Truist Securities Reiterates BioXcel Therapeutics (BTAI) at Buy, $125 Price TargetApril 6, 2022 12:10 PM BioXcel Therapeutics (BTAI) PT Raised to $76 at JefferiesApril 6, 2022 11:40 AM BioXcel Therapeutics (BTAI) PT Raised to $80 at BofA SecuritiesApril 6, 2022 11:09 AM Pre-Open Stock Movers 04/06: (TUFN) (BTAI) (TLRY) Higher; (CANO) (CAR) (JBLU) Lower (more...)April 6, 2022 9:02 AM BioXcel Therapeutics (BTAI) Announces FDA Approval of IGALMI Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in AdultsApril 6, 2022 7:00 AM BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in AdultsApril 6, 2022 7:00 AM BioXcel Therapeutics (BTAI) Halted, News PendingApril 6, 2022 6:56 AM